ReoPro data

Clinical investigators presented interim data on the company's CAPTURE study of the GPIIb/IIIa inhibitor in patients with unstable angina. CNTO disclosed initial results in December (see BioCentury Extra, Dec. 21, 1995).

On the composite end point of death, heart attack and urgent intervention at 30 days, the 513 ReoPro patients had an event rate of 10.8 percent vs. 16.4 percent in the 533 patients in the placebo group, a 34 percent reduction (p=0.0064). ...